Hepatic osteodystrophy

Hepatology

Volumn 33, Issue 1, 2001, Pages 301-307

  Rouillard, Smita ^a   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RISEDRONIC ACID; TESTOSTERONE; VITAMIN D;

CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HORMONE SUBSTITUTION; HUMAN; LIVER DISEASE; METABOLIC BONE DISEASE; NONHUMAN; NUTRITIONAL SUPPORT; OSTEODYSTROPHY; OSTEOMALACIA; OSTEOPOROSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0035196531     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.20533     Document Type: Article

References (86)

1. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease
2. Osteoporosis in primary biliary cirrhosis: Effects of 25-hydroxyvitamin D treatment
3. Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D
4. Bone disease in primary biliary cirrhosis: Increased bone resorption and turnover in the absence of osteoporosis or osteomalacia
5. Bone histomorphometry and structure in corticosteroid-treated chronic active hepatitis
6. Bone and mineral metabolism and chronic alcohol abuse
7. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change
8. Osteoporosis in chronic liver disease: Pathogenesis, risk factors, and management
9. Growth hormone, insulin-like growth factors and bone remodeling
10. The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse ostoblasts: Autocrine/paracrine growth effects of IGF's?
11. Osteopenia in rats with liver cirrhosis: Beneficial effects of IGF-I treatment
12. Somatomedin production in normal adults and cirrhotic patients
13. Serum growth hormone-binding protein, insulin-like growth factor-1 and growth hormone in patients with liver cirrhosis
14. Bone mineral density, serum insuli-like growth factor I, and bone turnover markers in viral cirrhosis
15. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice
16. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis
17. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis
18. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma
19. Bone changes in alcoholic cirrhosis of the liver. A histomorphometric study
20. Effects of alcohol ingestion on bone and mineral metabolism in rats
21. Bone disease in cholestatic liver disease
22. Editorial: 25-Hydroxyvitamin D treatment of bone disease in primary biliary cirrhosis
23. The metabolic bone disease of primary sclerosing cholangitis
24. Bone loss and reduced osteoblast function in primary biliary cirrhosis
25. Prediction of bone mineral density from vitamin D receptor alleses
26. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis
27. Calcium absorption on high and low calcium intake in relation to vitamin D receptor genotype
28. Vitamin D receptor genotypes and intestinal calcium absorption in postmenopausal women
29. Genetic influences on bone mineral density: Physiological correlates of vitamin D receptor alleles in premenopausal women
30. Bone disease in liver transplant recipients: Incidence, timeing and risk factors
31. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis
32. Metabolic bone disease in primary biliary cirrhosis at presentation
33. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis
34. Hepatic osteodystrophy in primary biliary cirrhosis: Effects of medical treatment
35. Vitamin-D receptor genotypes as independent genetic predictors of decreased bone mineral density in primary bilairy cirrhosis
36. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
37. Clucocorticoids and osteoporosis
38. Bone disease in liver transplant recipients
39. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation
40. Bone loss after liver transplantation
41. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat
42. Deleterious effects of longterm cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo
43. The role of testosterone in cyclosporin-induced osteopenia
44. Guidelines for the clinical utilization of bone mass measurement in the adult population
45. Site of bone density measurement may affect therapy decision
46. Osteoporosis and skeletal fractures in chronic liver disease
47. Bone loss after orthotopic liver transplantation
48. Osteoporosis and exercise
49. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis
50. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis
51. Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D
52. Metabolic bone disease in alcoholic cirrhosis: A comparison of the effect of vitamin D, 25-hydroxyvitamin D, or supportive treatment
53. Calcitriol for bone loss in patients with primary biliary cirrhosis
54. Calcitriol for bone disease in patients with cirrhosis of the liver
55. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemachromatosis
56. Estrogen-induced cholestasis: Clues to pathogenesis and treatment
57. Hormone replacement therapy in chronic active hepatitis: A case report
58. Estrogen-progesterone therapy for low bone mineral density in primary biliary cirrhosis
59. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
60. 17-Beta-Estradiol prevents osteopenia in oophorectomized rats treated with cyclosporin-A
61. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study
62. Effects of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis
63. Analgesic effect of calcitonin in osteoporotic vertebral fractures. A double-blind placebo controlled study
64. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium and calcitonin for severe osteodystrophy in primary biliary cirrhosis
65. Prevention of corticosteroid osteoporosis
66. Salmon calcitonin prevents cyclosporin A induced high turnover bone loss
67. Calcitonin and bisphophonates treatment in bone loss after liver transplantation
68. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
69. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial
70. Intermittant etidronate therapy to prevent corticosteroid-induced osteoporosis
71. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
72. Alendronate for the prevention of glucocorticoid-induced osteoporosis
73. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve month multicenter randomized doubleblind, placebo-controlled parallel group study
74. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study
75. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation
76. Editorial: Fluoride and bone - Quantity versus quality
77. Treatment with fluoride
78. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
79. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial
80. Sodium fluoride prevents bone loss in primary biliary cirrhosis
81. Treatment of osteoporosis after liver transplantation
82. Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?
83. Interferon alpha and gamma inhibit interleukin 1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures
84. Effect of interferon alpha on bone metabolism in patients with chronic hepatitis
85. Organ transplantation and osteoporosis